Despite macroeconomic challenges, the biotech industry performed relatively well due to inelastic demand for its products and services. Moreover, government initiatives, technological developments, and the biotech ingredients market, which assists businesses in making correct and up-to-date decisions, are all fueling the biotech industry’s expansion.
So, investors could consider buying shares of Vertex Pharmaceuticals Incorporated (VRTX), Biogen Inc. (BIIB), Exelixis, Inc. (EXEL), and Cidara Therapeutics, Inc. (CDTX) in 2023.
